V67A Stock Chart & Stats
€0.18
-€0.01(-5.68%)
At close: 4:00 PM EDT
€0.18
-€0.01(-5.68%)
Day’s Range― - ―
52-Week Range€0.15 - €1.06
Previous CloseN/A
Volume0.00
Average Volume (3M)3.85K
Market Cap
€21.96M
Enterprise Value€25.04
Total Cash (Recent Filing)€1.84M
Total Debt (Recent Filing)€15.98M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 17, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding100,633,770
10 Day Avg. Volume561
30 Day Avg. Volume3,853
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.82
Price to Sales (P/S)0.23
P/FCF Ratio-1.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€75.70M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthTop-line growth indicates that Cosmos is expanding sales of its pharmaceutical and nutraceutical products across healthcare channels. If maintained, this larger revenue base can improve operating leverage, support broader commercialization, and strengthen the company’s ability to scale its distribution platform.
Debt ReductionThe substantial reduction in debt improves financial flexibility and lowers balance-sheet pressure relative to earlier years. A smaller debt burden can reduce refinancing needs, preserve more capital for operations, and provide greater resilience while management works to improve profitability and cash generation.
Capital-Raising And Governance FlexibilityApproved governance and financing tools give Cosmos additional flexibility to support incentives, raise capital, or fund strategic needs. The continued director and auditor support also reinforces the existing governance framework, which may help management execute its commercialization strategy over coming quarters.
Bears Say
Thin Margins And Persistent LossesVery low gross profitability leaves limited room to absorb operating expenses, while the large operating and net losses show that revenue growth is not yet translating into sustainable earnings. Continued losses could constrain reinvestment, weaken shareholder returns, and pressure the balance sheet over time.
Ongoing Cash BurnPersistent negative operating and free cash flow means the business is consuming cash rather than funding itself internally. If this pattern continues, Cosmos may need external financing or further balance-sheet actions, reducing financial flexibility and making growth more dependent on capital availability.
Potential Equity DilutionAdditional equity and preferred-stock authorization can help fund the business, but issuing these securities could dilute existing common shareholders or introduce new financing terms. That risk is particularly material while the company remains loss-making and cash flow negative, potentially limiting per-share value creation.
Cosmos Holdings News
V67A FAQ
What was Cosmos Holdings Inc’s price range in the past 12 months?
Cosmos Holdings Inc lowest stock price was €0.15 and its highest was €1.06 in the past 12 months.
What is Cosmos Holdings Inc’s market cap?
Cosmos Holdings Inc’s market cap is €21.96M.
When is Cosmos Holdings Inc’s upcoming earnings report date?
Cosmos Holdings Inc’s upcoming earnings report date is Nov 17, 2026 which is in 65 days.
How were Cosmos Holdings Inc’s earnings last quarter?
Cosmos Holdings Inc released its earnings results on Aug 19, 2026. The company reported -€0.086 earnings per share for the quarter.
Is Cosmos Holdings Inc overvalued?
According to Wall Street analysts Cosmos Holdings Inc’s price is currently Overvalued.
Does Cosmos Holdings Inc pay dividends?
Cosmos Holdings Inc does not currently pay dividends.
What is Cosmos Holdings Inc’s EPS estimate?
Cosmos Holdings Inc’s EPS estimate is -0.04.
How many shares outstanding does Cosmos Holdings Inc have?
Cosmos Holdings Inc has 100,633,770 shares outstanding.
What happened to Cosmos Holdings Inc’s price movement after its last earnings report?
Cosmos Holdings Inc reported an EPS of -€0.086 in its last earnings report. Following the earnings report the stock price went up 9.524%.
Which hedge fund is a major shareholder of Cosmos Holdings Inc?
Currently, no hedge funds are holding shares in DE:V67A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cosmos Holdings Inc
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.